株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非侵襲癌診断市場 (第2版):2017〜2030年

Non-Invasive Cancer Diagnostics Market, 2nd Edition, 2017 - 2030

発行 ROOTS ANALYSIS 商品コード 344666
出版日 ページ情報 英文 425 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
非侵襲癌診断市場 (第2版):2017〜2030年 Non-Invasive Cancer Diagnostics Market, 2nd Edition, 2017 - 2030
出版日: 2017年05月17日 ページ情報: 英文 425 Pages
概要

当レポートは、世界の非侵襲癌診断市場について取り上げ、各種の癌診断に用いられる上市・開発中のリキッドバイオプシーキット/アッセイ、およびその他の新しい・有望な非侵襲診断に関する調査を提供しており、市場の概要、市場規模と予測、および主要企業のプロファイルなどをまとめ、お届け致します。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 癌統計・疾病負担
  • 癌における早期発見の重要性
  • 癌検出:検査 vs. 診断
  • 従来型の侵襲性癌診断検査
    • 生検
    • 内視鏡
  • 非侵襲アプローチの必要性
  • 非侵襲検査関連のコスト・メリット

第4章 非侵襲癌スクリーニング・診断のコンセプト

  • 本章の概要
  • 診断画像
  • スクリーニングアッセイ
  • 先進非侵襲アプローチ

第5章 市場情勢

  • 本章の概要
  • リキッドバイオプシー
  • リキッドバイオプシー:技術、プラットフォーム、システムおよび装置

第6章 リキッドバイオプシー市場:主な考察

  • 本章の概要
  • リキッドバイオプシー検査:ディベロッパーの競合情勢
  • リキッドバイオプシー検査:アプリケーションの分布・標的となる症状
  • ソーシャルメディアにおける非侵襲癌診断の新興動向

第7章 リキッドバイオプシー:詳細展望

  • 本章の概要
  • 癌の検出に生検を上回る低侵襲手法
  • 癌向け循環バイオマーカー
  • リキッドバイオプシー型検査・システム
  • コンパニオンリキッドバイオプシー:近年の発展

第8章 ベンチャーキャピタル資金

  • 本章の概要
  • 資金の種類
  • リキッドバイオプシー市場:資金例
  • リキッドバイオプシー市場:年度別の分布
  • リキッドバイオプシー市場:モデルタイプの分布
  • 主要企業:資金例による分布

第9章 企業評価分析

  • 本章の概要
  • 企業評価:調査手法
  • 企業評価:マルチパラメーターによる分類
  • 企業評価:Roots Analysis独自のスコア

第10章 リキッドバイオプシー:主要企業

  • 本章の概要
  • Biocartis
  • Biocept
  • Biodesix
  • Exosome Diagnostics
  • Genomic Health
  • Guardant Health
  • NeoGenomics Laboratories
  • Personal Genome Diagnostics (PGDx)
  • QIAGEN
  • Transgenomic
  • Trovagene

第11章 その他の非侵襲癌診断

  • 本章の概要
  • 非血液ベースのバイオマーカー検出検査
  • DNAメチル化検出検査
  • 便潜血反応検査 (FOBT) ・免疫便潜血検査 (FIT)
  • マイクロRNA (miRNA) ベース検査
  • 便DNA (sDNA) 検査
  • 揮発性有機化合物 (VOC) 検出検査
  • その他の非侵襲癌診断:市場情勢
  • その他の非侵襲癌診断:調査分析

第12章 市場規模・予測

  • 本章の概要
  • 予測の前提条件・予測手法
  • 非侵襲癌診断市場の予測

第13章 結論

第14章 インタビュー記録

第15章 付録1:表形式のデータ

第16章 付録2:企業と組織の一覧

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10081

Cancer is an extremely complex disease and medical science is still struggling to figure out the reasons and factors that influence the disease origin, propagation, spread (metastasis) and relapse. In 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer. The high cancer mortality rate is primarily due to delay in detection of the disease. Therefore, in addition to satisfying the unmet market need for advanced and efficient treatment interventions, early cancer diagnosis and screening form an important component of disease prevention and cure. Early diagnosis increases the survival rate that is unlikely to happen if the disease is identified at an advanced stage.

Invasive cancer diagnostic methods such as tissue biopsies have been the gold standard to determine the clinico-pathological characteristics of cancer tissues for many years. The procedure is not only cost-intensive but is also a traumatic experience for the patients. Additionally, endoscopies such as colonoscopy, gastroscopy and laparoscopy are also employed for cancer diagnosis. However, biopsies and endoscopies only offer insights of the disease state at a single point of time. They are unable to measure the disease progression or monitor the effects of the administered therapy over the treatment period. Therefore, the current cancer diagnostics market faces a pressing need for more accurate non-invasive methods of diagnosis to ensure better patient care.

There are several advanced approaches that are not only non-invasive / minimally invasive but also outweigh the limitations posed by invasive diagnostic procedures. Liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool that analyzes biofluids (blood, urine or plasma) to detect rare cells and biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs) or exosomes. Moreover, liquid biopsies are capable of not only analyzing the tumor state at the time of sample extraction but can also monitor and track changes in tumor genetics over the course of treatment. In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies that exploit skin lesions, bronchial fluid and exhaled breath as samples to trace signatures of cancer. These tests use gene expression profiles, biomarker analysis, volatile organic compound detection and other advanced techniques of molecular genetics to identify a particular cancer indication.

These non-invasive diagnostic techniques, backed by patient success stories, awareness and the availability of successful clinical validation data for several cancer indications, hold a significant promise and are anticipated to replace the existing invasive diagnostic tools in the coming few years. In fact, social media platforms, such as Twitter, have witnessed an increasing volume of tweets over the years. Between 2010 and 2016, we were able to identify over 7,000 tweets; this clearly indicates an upsurge in the popularity of these non-invasive tests in the given time period. With liquid biopsy on the forefront, the overall non-invasive cancer diagnostics market is likely to receive a significant boost in the near future.

Synopsis:

The ‘Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030’ report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. The market is characterized by the presence of several companies that have proprietary technologies / platforms for either isolation / enrichment / enumeration of CTCs or for molecular characterization / sequencing of the genetic material extracted from the CTCs / exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, and patient and recurrence monitoring of different cancer indications. Such kits are likely to transform the cancer diagnostics market with many commercial success stories in the near future.

The market is primarily led by start-ups / small companies, such as (in alphabetical order) CellMax Life, Celsee Diagnostics, Datar Genetics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences, iCellate Medical, Inivata, IVDiagnostics, LCM Genect and MDNA Life Sciences. It also has presence of mid to large-sized pharma players; notable examples include (in alphabetical order) Biocartis, Counsyl, Foundation Medicine, Genomic Health and NeoGenomics Laboratories. In addition to the aforementioned players, a number of pharma giants are also developing assets in this field. Prominent players under this category include (in alphabetical order) Affymetrix, Menarini Silicon Biosystems, Myriad Genetics, QIAGEN, Roche, Siemens Healthineers and Thermo Fisher Scientific.

As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives of this report was to understand the future potential of the market. Amongst other elements, the report provides information on:

  • The overall landscape of liquid biopsies and other novel non-invasive diagnostic tests with respect to the stage of development, type of markers (CTCs / ctNA / exosomes), test sample source (blood / urine / others), indications and type of application (early diagnosis / recurrence monitoring / patient monitoring). Additionally, the market overview highlights the geographical distribution and coverage of the tests across the globe, depicting the activity of this domain in different regions of the world.
  • Comprehensive profiles of the popular tests and systems highlighting details on development status, specifications and advantages, clinical information, and related collaborations. Additionally, we have provided detailed profiles of the key players involved in the domain.
  • The impact of venture capital funding in this area. It is important to mention that since the industry has witnessed the emergence of several start-ups, funding is a key enabler that is likely to drive both innovation and product development in the coming years.
  • An elaborate valuation analysis of start-ups and small players that are involved in the liquid biopsy domain. We built a multi-variable dependent valuation model to estimate the current valuation of a number of companies focused in this domain.
  • The emerging trends and the popularity of liquid biopsy on social media platforms, such as Twitter, over the last few years. The volume of tweets has witnessed an increasing trend in the last six years, influenced by the approval and launch of several liquid biopsy tests in the market.
  • The competitive landscape of the players involved in the space. This is represented as an illustrative bubble analysis, which is based on parameters such as the liquid biopsy portfolio of a company, its number of employees and geographical coverage of the tests.
  • Contribution of the other non-invasive cancer diagnostics market, taking into account the number of tests and the sales registered by the marketed tests.

In addition, we have provided a comprehensive market estimation to determine the global evolution of the liquid biopsy market. This has been done by evaluating the likely success of key applications of early diagnosis, recurrence monitoring and patient monitoring. We have included insights on the likely regional evolution of the market covering US, EU5 and rest of the world. In addition, we have estimated the likely contribution of different target patient populations to the global market; this covered key indications including (in alphabetical order) bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. Further, we segmented the market by the type of markers (CTCs, ctNAs, exosomes) and the sample source (blood, urine, saliva) used in different liquid biopsies. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the time period 2017-2030. The conservative, base and optimistic scenarios represent three different tracks of the industry's evolution. The research, analysis and insights presented in this report are backed by the deep understanding of key insights gathered from both secondary and primary research.

Our opinions and insights presented in this study were influenced by discussions that we conducted with several experts in this area. These included contributions from (in alphabetical order of companies) Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Frank Szczepanski (President and CEO, IVDiagnostics), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Nathalie Bernard (Marketing Director, OncoDNA), Abizar Lakdawalla (Founder, ProXeom), Mark Li (CEO, Resolution Bioscience) and Jake Micallef (Chief Scientific Officer, VolitionRx). All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. We identified over 110 liquid biopsy tests; of these, 60% of the tests are currently available for patients while the remaining are either available for research use only (RUO) or are under development. Further, of the total tests, 36% detect the presence of ctDNA in the sample, nearly 41% detect CTCs and 4% validate the presence of exosomes. Close to 19% of the liquid biopsy tests identify the presence of multiple / other markers.
  • 2. Seven liquid biopsy tests are being explored for use as companion diagnostics. Many partnerships have been inked to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between BMS and GRAIL (2017), Merck and Sysmex Inostics (2016), Biocept and Baylor College of Medicine (2015), QIAGEN and Tokai Pharmaceuticals (2015), ANGLE and MD Anderson Cancer Center (2015), and AstraZeneca and QIAGEN (2015).
  • 3. Considering the future potential of these diagnostic kits and systems, several investors have made substantial capital commitment to drive future development. We identified approximately 196 funding instances amounting to capital investments (equity / debt / grants) of over USD 3.8 billion between 2011 and 2017; these investments were made either directly or indirectly to support the development of liquid biopsy products. In 2016 alone, driven by increased venture capital activity, amount worth USD 770 million was invested in different companies.
  • 4. With the rising activity in the field of cancer diagnostics, pharmaceutical players have been keen to explore the acquisition opportunities in this domain. In the Roots Analysis proprietary valuation analysis of over 40 start-ups / small companies, we identified nine companies that are likely to achieve valuation of over USD 500 million.
  • 5. The market, primarily driven by the sales generated by liquid biopsy tests, is anticipated to register a growth rate of 19% between 2017 and 2030. The current market is dominated by the tests that offer patient monitoring (63% share). Specifically, catering to the high unmet need for timely treatment, the share of early diagnosis is likely to increase from 20% in 2017 to over 40% by 2030.
  • 6. Among specific indications, we believe that prostate cancer is likely to capture the largest share of the market (~15%). Subsequently, owing to the large target patient population, breast cancer is likely to capture a share of 14% by 2030. In addition, lung cancer is also likely to capture a significant market share of 12% by 2030. It is worth highlighting that, despite the low prevalence of lung cancer, the demand of liquid biopsies is significantly high as tissue biopsy is extremely difficult in case of lungs.
  • 7. With regard to the geographical activity, in 2017, the US is likely to capture the maximum share (43%) followed by EU5 (34%) and Rest of the World (RoW, 23%). The overall trend is unlikely to change significantly in 2030; however, regions in RoW are likely to occupy a larger share in 2030 (29%). It is important to highlight that, within RoW, Asian countries such as China, India, Japan, have several developers and distributors of liquid biopsy tests, demonstrating an elevating activity within these regions.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming 10-15 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 presents an executive summary of the report. It offers a high level view on where the market for liquid biopsy and other novel non-invasive diagnostics is headed in the mid to long term.

Chapter 3 provides a general introduction to cancer statistics and the global burden of the disease. In this section, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

Chapter 4 discusses, in detail, the need for non-invasive cancer diagnostics and their importance. We have highlighted the underlying concept of liquid biopsy and other non-invasive tests. In addition, we have mentioned the principle behind common imaging tests that are deployed in cancer diagnosis.

Chapter 5 provides a holistic view of the liquid biopsy market. It lists the liquid biopsy tests, technologies and systems. In addition, the chapter includes a detailed analysis of the liquid biopsy tests based on the development stage (available for patients / RUO / under development), sample type (blood / plasma / urine / multiple), type of markers detected (CTCs / ctNA (DNA) / exosomes / multiple / others), indication and type of application (early detection / patient monitoring / recurrence monitoring).

Chapter 6 offers an illustrative bubble analysis representing the competitive landscape of the players involved in the space, based on their liquid biopsy portfolio, number of employees and geographical coverage. In addition, it presents a Venn diagram depicting the distribution of liquid biopsy products across different application areas. The chapter elucidates the emerging trends and the popularity of liquid biopsy on social media platforms, such as Twitter, over the last few years.

Chapter 7 offers a comprehensive discussion on liquid biopsy. We have talked about the emerging need for liquid biopsy highlighting its advantages, and the related challenges. In addition, we have provided profiles of several liquid biopsy products and technologies. These products belong to those companies that were identified as active players in the bubble analysis presented in Chapter 6. The chapter also mentions the liquid biopsy companion diagnostics, which are being co-developed as part of strategic collaborations.

Chapter 8 presents details on the investments and grants received by companies working in the field of liquid biopsy. The analysis highlights the growing interest of the venture capital community and other strategic investors in this market.

Chapter 9 features a comprehensive valuation analysis of the companies that are developing liquid biopsy tests / technologies / systems / platforms / instruments. The chapter provides insights based on a multi-variable dependent valuation model. The model is based on the future potential of the companies' uniqueness, their current popularity, funding received, year of establishment and the employed workforce.

Chapter 10 provides detailed company profiles of the leading players that are involved in the development of liquid biopsy tests. Amongst other details, each profile includes information such as the company overview, financial performance, product portfolio (technical specifications and clinical information) and recent collaborations.

Chapter 11 provides an overview of the other non-invasive diagnostics for oncology. It highlights different diagnostics tests, including non-blood based biomarker detection tests (saliva-based biomarker detection, stool-based metabolic biomarker detection, skin-based biomarker detection, semen-based biomarker detection and urine based biomarker detection), DNA methylation detection test, fecal occult blood test and fecal immunochemical test, MicroRNA (miRNA) based test, pigmented lesion assay, stool DNA (sDNA) testing, and Volatile Organic Compound (VOC) detection test. The diagnostic procedures discussed in this chapter are backed up by several examples. In addition, the chapter illustrates a detailed analysis on the survey conducted for gaining a deeper understanding on the nature of products and services offered by the companies.

Chapter 12 highlights the market forecast and sizing of the overall non-invasive cancer diagnostics market. This chapter discusses, in detail, the parameters that are likely to influence the evolution of liquid biopsy market. It features detailed insights on the likely market evolution for across different application areas such as early diagnosis, patient monitoring and recurrence monitoring. Additionally, the chapter presents a detailed market segmentation by the key indications, types of markers (CTCs, ctNAs, exosomes) and types of samples (blood, urine, saliva). The chapter also highlights the likely distribution of the market across the US, EU5 and RoW (including Asia) regions. We have also presented an informed view on the contribution of the other non-invasive tests in the overall non-invasive cancer diagnostics market.

Chapter 13 summarizes the overall report. In this chapter, we have listed the key takeaways and have provided our independent opinion based on the research and analysis described in previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Frank Szczepanski (President and CEO, IVDiagnostics), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Nathalie Bernard (Marketing Director, OncoDNA), Abizar Lakdawalla (Founder, ProXeom), Mark Li (CEO, Resolution Bioscience) and Jake Micallef (Chief Scientific Officer, VolitionRx)

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Cancer Statistics and Burden of the Disease
  • 3.3. Importance of Early Detection in Cancer
  • 3.4. Detecting Cancer: Screening vs. Diagnosis
  • 3.5. Conventional Invasive Cancer Diagnostic Tests
    • 3.5.1. Biopsy
      • 3.5.1.1. Fine Needle Aspiration Biopsy
      • 3.5.1.2. Core Needle Biopsy
      • 3.5.1.3. Vacuum-Assisted Biopsy
      • 3.5.1.4. Image-Guided Biopsy
      • 3.5.1.5. Sentinel Node Biopsy
      • 3.5.1.6. Surgical Biopsy
      • 3.5.1.7. Endoscopic Biopsy
      • 3.5.1.8. Bone Marrow Biopsy
    • 3.5.2. Endoscopy
  • 3.6. Need for Non-Invasive Approaches
  • 3.7. Costs and Benefits Associated with Non-Invasive Tests

4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS

  • 4.1. Chapter Overview
  • 4.2. Diagnostic Imaging
    • 4.2.1. Magnetic Resonance Imaging (MRI)
    • 4.2.2. Mammography
    • 4.2.3. Bone Scan
    • 4.2.4. Computerized Tomography (CT) Scan
    • 4.2.5. Integrated PET-CT Scan
    • 4.2.6. Ultrasound
    • 4.2.7. Barium Enema
  • 4.3. Screening Assays
    • 4.3.1. Papanicolaou Test (Pap Test) and Human Papilloma Virus Test (HPV Test)
    • 4.3.2. Tumor Marker Test
    • 4.3.3. Fecal Occult Blood Tests (FOBT)
    • 4.3.4. Digital Rectal Exam (DRE)
    • 4.3.5. Multigated Acquisition (MUGA) Scan
  • 4.4. Advanced Non-Invasive Approaches
    • 4.4.1. Liquid Biopsy
    • 4.4.2. Cytogenetic / Gene Expression Studies
    • 4.4.3. Molecular Signature Based Non-Invasive Methods
    • 4.4.4. Saliva-Based Oral Cancer Diagnostics
    • 4.4.5. Vital Staining
    • 4.4.6. Optical Biopsy
    • 4.4.7. Other Techniques

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Liquid Biopsy: Development Landscape
    • 5.2.1. Liquid Biopsy Tests: Distribution by Development Stage
    • 5.2.2. Liquid Biopsy Tests: Distribution by Sample Type
    • 5.2.3. Liquid Biopsy Tests: Distribution by Type of Markers Detected
    • 5.2.4. Liquid Biopsy Tests: Distribution by Indication
    • 5.2.5. Liquid Biopsy Tests: Distribution by Type of Application
    • 5.2.6. Liquid Biopsy Tests: Distribution by Geographical Coverage
    • 5.2.7. Liquid Biopsy Tests: Distribution by Leading Players
  • 5.3. Liquid Biopsy: Technologies, Platforms, Systems and Instruments

6. LIQUID BIOPSY MARKET: KEY INSIGHTS

  • 6.1. Chapter Overview
  • 6.2. Liquid Biopsy Tests: Competitive Landscape of Developers
  • 6.3. Liquid Biopsy Tests: Distribution by Application and Target Indications
  • 6.4. Emerging Trends on Non-Invasive Cancer Diagnostics on Social Media
    • 6.4.1. Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016)
    • 6.4.2. Non-Invasive Cancer Diagnostics: Twitter Word Cloud (2010, 2012, 2014, 2016)
    • 6.4.3. Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016)
    • 6.4.4. Non-Invasive Cancer Diagnostics: Twitter Trends for Samples Types (2010-2016)

7. LIQUID BIOPSY: DETAILED OUTLOOK

  • 7.1. Chapter Overview
  • 7.2. Non-Invasive Methods Over Biopsies for Detection of Cancer
  • 7.3. Circulating Biomarkers for Cancer
    • 7.3.1. Circulating Tumor Cells (CTCs)
      • 7.3.1.1. Advantages Associated with the Use of CTCs
      • 7.3.1.2. Challenges Associated with the Use of CTCs
    • 7.3.2. Circulating Tumor DNA (ctDNA)
    • 7.3.3. Exosomes
  • 7.4. Liquid Biopsy Based Tests and Systems
    • 7.4.1. BioFluidica CTC Isolation Technology, CTC Analysis System and Test, BioFluidica / Roche
      • 7.4.1.1. Overview
      • 7.4.1.2. Specifications and Advantages
      • 7.4.1.3. Clinical Information
      • 7.4.1.4. Collaborations
    • 7.4.2. CancerIntercept™ Detect and CancerIntercept™ Monitor, Pathway Genomics
      • 7.4.2.1. Overview
      • 7.4.2.2. Specifications and Advantages
      • 7.4.2.3. Clinical Information
      • 7.4.2.4. Collaborations
    • 7.4.3. Cancertrack, Datar Genetics
      • 7.4.3.1. Overview
      • 7.4.3.2. Specifications and Advantages
      • 7.4.3.3. Clinical Information
      • 7.4.3.4. Collaborations
    • 7.4.4. CellMax-LBx Liquid Biopsy and CellMax-CRC Colorectal Cancer Blood Test, CellMax Life
      • 7.4.4.1. Overview
      • 7.4.4.2. Specifications and Advantages
      • 7.4.4.3. Clinical Information
      • 7.4.4.4. Collaborations
    • 7.4.5. CELLSEARCH® System and CELLSEARCH® CTC Test, Menarini Silicon Biosystems
      • 7.4.5.1. Overview
      • 7.4.5.2. Specifications and Advantages
      • 7.4.5.3. Clinical Information
      • 7.4.5.4. Collaborations
    • 7.4.6. cobas® EGFR Mutation Test v2, Roche
      • 7.4.6.1. Overview
      • 7.4.6.2. Specifications and Advantages
      • 7.4.6.3. Clinical Information
      • 7.4.6.4. Collaborations
    • 7.4.7. LiquidBiopsy® Rare Cell Isolation Platform, ClearID® Total Insight Breast Cancer, ClearID® Lung Cancer and Clear ID® Melanoma, Cynvenio Biosystems
      • 7.4.7.1. Overview
      • 7.4.7.2. Specifications and Advantages
      • 7.4.7.3. Clinical Information
      • 7.4.7.4. Collaborations
    • 7.4.8. Oncocount, Oncotrace, Oncotrial and Metastat, R.G.C.C. Group
      • 7.4.8.1. Overview
      • 7.4.8.2. Specifications and Advantages
      • 7.4.8.3. Clinical Information
    • 7.4.9. OncoBEAM™ CRC RAS Kit, Sysmex Inostics / Merck
      • 7.4.9.1. Overview
      • 7.4.9.2. Specifications and Advantages
      • 7.4.9.3. Clinical Information
      • 7.4.9.4. Collaborations
    • 7.4.10. OnTarget™ Assay, Boreal Genomics
      • 7.4.10.1. Overview
      • 7.4.10.2. Specifications and Advantages
      • 7.4.10.3. Clinical Information
      • 7.4.10.4. Collaborations
    • 7.4.11. PrediSeq-Prostate and PrediSeq-Lung, Predicine
      • 7.4.11.1. Overview
      • 7.4.11.2. Specifications and Advantages
      • 7.4.11.3. Clinical Information
      • 7.4.11.4. Collaborations
    • 7.4.12. SelectMDx™, MDxHealth
      • 7.4.12.1. Overview
      • 7.4.12.2. Specifications and Advantages
      • 7.4.12.3. Clinical Information
      • 7.4.12.4. Collaborations
    • 7.4.13. ViewRNA™ CTC Platform and Assay, Affymetrix
      • 7.4.13.1. Overview
      • 7.4.13.2. Specifications and Advantages
      • 7.4.13.3. Collaborations
    • 7.4.14. Velox™, IVDiagnostics
      • 7.4.14.1. Overview
      • 7.4.14.2. Collaborations
    • 7.4.15. ApoStream® System and Technology, ApoCell
      • 7.4.15.1. Overview
      • 7.4.15.2. Specifications and Advantages
      • 7.4.15.3. Clinical Information
      • 7.4.15.4. Collaborations
    • 7.4.16. IsoPic™, iCellate Medical
      • 7.4.16.1. Overview
      • 7.4.16.2. Specifications and Advantages
      • 7.4.16.3. Clinical Information
      • 7.4.16.4. Collaborations
    • 7.4.17. Parsortix™ System, ANGLE
      • 7.4.17.1. Overview
      • 7.4.17.2. Specifications and Advantages
      • 7.4.17.3. Clinical Information
      • 7.4.17.4. Collaborations
  • 7.5. Companion Liquid Biopsies: Recent Developments
    • 7.5.1. Biocept and Baylor College of Medicine
    • 7.5.2. Tokai Pharmaceuticals and QIAGEN
    • 7.5.3. ANGLE and MD Anderson Cancer Center
    • 7.5.4. AstraZeneca and QIAGEN
    • 7.5.5. Sysmex Inostics and Bayer Healthcare

8. VENTURE CAPITAL FUNDING

  • 8.1. Chapter Overview
  • 8.2. Types of Funding
  • 8.3. Liquid Biopsy Market: Funding Instances, 2011-2017
  • 8.4. Liquid Biopsy Market: Distribution by Year
  • 8.5. Liquid Biopsy Market: Distribution of Type of Model
  • 8.6. Leading Players: Distribution by Funding Instances

9. COMPANY VALUATION ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Company Valuation: Methodology
  • 9.3. Company Valuation: Categorization by Multiple Parameters
    • 9.3.1. Categorization by Google Hits Score
    • 9.3.2. Categorization by Awards Score
    • 9.3.3. Categorization by Twitter Score
    • 9.3.4. Categorization by Twitter Followers Score
    • 9.3.5. Categorization by Number of Products
    • 9.3.6. Categorization by Uniqueness Score
    • 9.3.7. Categorization by Weighted Average Score
  • 9.4. Company Valuation: Roots Analysis Proprietary Scores

10. LIQUID BIOPSY: KEY PLAYERS

  • 10.1. Chapter Overview
  • 10.2. Biocartis
  • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
      • 10.2.3.1. Idylla™ ctBRAF Mutation Assay (RUO)
      • 10.2.3.2. Idylla™ ctKRAS Mutation Assay
      • 10.2.3.3. Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO)
    • 10.2.4. Collaborations
  • 10.3. Biocept
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
      • 10.3.3.1. Target Selector™ Breast Cancer Test
      • 10.3.3.2. Target Selector™ Lung Cancer Test
      • 10.3.3.3. Target Selector™ Immuno-Oncology PD-L1 Test
      • 10.3.3.4. Target Selector™ Gastric Cancer Test
      • 10.3.3.5. Target Selector™ Colorectal Cancer Test
      • 10.3.3.6. Target Selector™ Prostate Cancer Test
      • 10.3.3.7. Target Selector™ Melanoma Test
    • 10.3.4. Collaborations
  • 10.4. Biodesix
    • 10.4.1. Company Overview
    • 10.4.2. Financial Information
    • 10.4.3. Product Portfolio
      • 10.4.3.1. GeneStrat®
      • 10.4.3.2. VeriStrat®
    • 10.4.4. Collaborations
  • 10.5. Exosome Diagnostics
    • 10.5.1. Company Overview
    • 10.5.2. Financial Information
    • 10.5.3. Product Portfolio
      • 10.5.3.1. ExoDx™ Prostate (IntelliScore)
      • 10.5.3.2. ExoDx™ Lung (ALK)
      • 10.5.3.3. ExoDx™ Lung (EGFR/T790M)
      • 10.5.3.4. ExoDx™ Solid Tumor
    • 10.5.4. Collaborations
  • 10.6. Genomic Health
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
      • 10.6.3.1. Oncotype SEQ™ Liquid Select
    • 10.6.4. Collaborations
  • 10.7. Guardant Health
    • 10.7.1. Company Overview
    • 10.7.2. Financial Information
    • 10.7.3. Product Portfolio
      • 10.7.3.1. Guardant360™
    • 10.7.4. Collaborations
  • 10.8. NeoGenomics Laboratories
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
      • 10.8.3.1. NeoLAB™ HEME
      • 10.8.3.2. NeoLAB™ Solid Tumor Monitor (NeoLAB SOLID TUMOR)
      • 10.8.3.3. NeoLAB™ Prostate
      • 10.8.3.4. NeoLAB™ EGFR T790M Liquid Biopsy
    • 10.8.4. Clinical Information
    • 10.8.5. Collaborations
  • 10.9. Personal Genome Diagnostics (PGDx)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Information
    • 10.9.3. Product Portfolio
      • 10.9.3.1. MetDETECT™
      • 10.9.3.2. PlasmaSELECT™ R 64
      • 10.9.3.3. LungSELECT™
    • 10.9.4. Collaborations
  • 10.10. QIAGEN
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
      • 10.10.3.1. AdnaTest Technology (Acquired from AdnaGen)
      • 10.10.3.2. therascreen® EGFR RGQ PCR Kit
      • 10.10.3.3. Sample Preparation Kits
    • 10.10.4. Collaborations
  • 10.11. Transgenomic
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
      • 10.11.3.1. MX-ICP CRC Analysis
      • 10.11.3.2. MX-ICP Melanoma Analysis
      • 10.11.3.3. MX-ICP NSCLC Analysis
    • 10.11.4. Collaborations
  • 10.12. Trovagene
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
      • 10.12.3.1. Trovera™ BRAF Mutation Detection
      • 10.12.3.2. Trovera™ EGFR Mutation Detection
      • 10.12.3.3. KRAS Mutation Detection
      • 10.12.3.4. HPV HR Detection Test
    • 10.12.4 Collaborations

11. OTHER NON-INVASIVE CANCER DIAGNOSTICS

  • 11.1. Chapter Overview
  • 11.2. Non-Blood Based Biomarker Detection Tests
  • 11.3. DNA Methylation Detection Tests
  • 11.4. Fecal Occult Blood Test (FOBT) AND Fecal Immunochemical Test (FIT)
  • 11.5. MicroRNA (miRNA) Based Test
  • 11.6. Pigmented Lesion Assay
  • 11.7. Stool DNA (sDNA) Testing
  • 11.8. Volatile Organic Compound (VOC) Detection Test
  • 11.9. Other Non-Invasive Cancer Diagnostics: Market Landscape
  • 11.10. Other Non-Invasive Cancer Diagnostics: Survey Analysis
    • 11.10.1. Survey Analysis: Seniority Level of Respondents
    • 11.10.2. Survey Analysis: Type of Product Portfolio
    • 11.10.3. Survey Analysis: Types of Products / Services Offered
    • 11.10.4. Survey Analysis: Type of Application
    • 11.10.5. Survey Analysis: Availability of the Products
    • 11.10.6. Survey Analysis: Likely Market Size

12. MARKET SIZING AND FORECAST

  • 12.1. Chapter Overview
  • 12.2. Forecast Assumptions and Methodology
  • 12.3. Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030
    • 12.3.1. Liquid Biopsy Market Forecast, 2017-2030
      • 12.3.1.1. Liquid Biopsy Market Forecast: Distribution by Application
      • 12.3.1.2. Liquid Biopsy Market Forecast: Distribution by Indication
      • 12.3.1.3. Liquid Biopsy Market Forecast: Distribution by Type of Marker
      • 12.3.1.4. Liquid Biopsy Market Forecast: Distribution by Type of Sample
      • 12.3.1.5. Liquid Biopsy Market Forecast: Distribution by Geography
    • 12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030

13. CONCLUSION

  • 13.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology
  • 13.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management
  • 13.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
  • 13.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications
  • 13.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies
  • 13.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation
  • 13.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
  • 13.8. Primarily Led by Liquid Biopsy, The Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. Burkhard Jansen, MD, Chief Medical Officer, DermTech
  • 14.3. Frank Szczepanski, President and CEO, IVDiagnostics
  • 14.4. Riccardo Razzini, Sales and Marketing Manager, LCM Genect
  • 14.5. Nathalie Bernard, Marketing Director, OncoDNA
  • 14.6. Abizar Lakdawalla, Founder, ProXeom
  • 14.7. Mark Li, CEO, Resolution Bioscience
  • 14.8. Christer Ericsson, Chief Scientific Officer, iCellate Medical
  • 14.9. Philippe Nore, CEO and Co-founder, MiNDERA
  • 14.10. Jake Micallef, Chief Scientific Officer, VolitionRx

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Worldwide Incidence of Cancer: Distribution by Type
  • Figure 3.2: Lung Cancer: Estimated New Cases in 2016 (In Thousands)
  • Figure 3.3: Breast Cancer: Estimated New Cases in 2016 (In Thousands)
  • Figure 3.4: Colorectal Cancer: Estimated New Cases in 2016 (In Thousands)
  • Figure 3.5: Factors Determining Useful Cancer Screening
  • Figure 3.6: Conventional Cancer Diagnosis Methods
  • Figure 3.7: Disadvantages of Conventional Cancer Diagnosis Methods
  • Figure 3.8: Traditional Biopsy: Process Flow
  • Figure 3.9: Non-Invasive Biopsy: Process Flow
  • Figure 4.1: Broad Categories of Non-Invasive Cancer Screening and Diagnostics
  • Figure 4.2: Types of Diagnostic Imaging
  • Figure 4.3: Types of Screening Assays
  • Figure 4.4: Types of Advanced Non-Invasive Approaches
  • Figure 5.1: Liquid Biopsy Tests: Distribution by Development Stage
  • Figure 5.2: Liquid Biopsy Tests: Distribution by Sample Type
  • Figure 5.3: Liquid Biopsy Tests: Distribution by Type of Markers Detected
  • Figure 5.4: Liquid Biopsy Tests: Distribution by Indication
  • Figure 5.5: Liquid Biopsy Tests: Distribution by Type of Application
  • Figure 5.6: Liquid Biopsy Tests: Distribution by Leading Players
  • Figure 6.1: Liquid Biopsy Competitive Landscape: Established Players
  • Figure 6.2: Liquid Biopsy Competitive Landscape: Mid-Sized Players
  • Figure 6.3: Liquid Biopsy Competitive Landscape: Start-ups
  • Figure 6.4: Liquid Biopsy Tests (Available for Patients): Distribution by Application and Target Indications
  • Figure 6.5: Liquid Biopsy Tests (Available for RUO / Under Development): Distribution by Application and Target Indications
  • Figure 6.6: Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016)
  • Figure 6.7: Non-Invasive Cancer Diagnostics: Twitter World Cloud (2010, 2012, 2014, 2016)
  • Figure 6.8: Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016)
  • Figure 6.9: Non-Invasive Cancer Diagnostics: Twitter Trends for Sample Type (2010-2016)
  • Figure 7.1: Circulating Biomarkers for Cancer Detection
  • Figure 7.2: BioFluidica CTC Isolation System: Steps of Operation
  • Figure 7.3: BioFluidica CTC Isolation System: Advantages
  • Figure 7.4: CellMax's Liquid Biopsy: Steps of Operation
  • Figure 7.5: CELLSEARCH® System: Steps of Operation
  • Figure 7.6: cobas® EGFR Mutation Test v2: Steps of Operation
  • Figure 7.7: LiquidBiopsy® Rare Cell Isolation Platform: Steps of Operation
  • Figure 7.8: LiquidBiopsy® Rare Cell Isolation Platform and Ion Torrent™ PGM Workflow Components
  • Figure 7.9: OnTarget™ Assay: Steps of Operation
  • Figure 7.10: PrediSeq: Steps of Operation
  • Figure 7.11: ViewRNA™ CTC Platform: Steps of Operation
  • Figure 7.12: Apostream® Technology: Advantages
  • Figure 7.13: IsoPic™ Instrument: Steps of Operation
  • Figure 7.14: Parsortix™ System: Steps of Operation
  • Figure 8.1: Liquid Biopsy Market: Cumulative Funding Instances, 2011-2017
  • Figure 8.2: Liquid Biopsy Market: Cumulative Funding Amount, 2011-2017 (USD Billion)
  • Figure 8.3: Liquid Biopsy Market: Distribution by Type of Funding Instances, 2011-2017
  • Figure 8.4: Liquid Biopsy Market: Distribution by Total Amount Invested, 2011-2017 (USD Billion)
  • Figure 8.5: Liquid Biopsy Market: Distribution by Amount Invested and Type of Funding (USD Billion)
  • Figure 8.6: Leading Players: Distribution by Number of Funding Instances
  • Figure 9.1: Company Valuation Analysis: A/F Ratio, Input Dataset
  • Figure 9.2: Company Valuation Analysis: A/Y Ratio, Input Dataset
  • Figure 9.3: Company Valuation Analysis: A/E Ratio, Input Dataset
  • Figure 9.4: Company Valuation Analysis: Categorization by Google Hits Score
  • Figure 9.5: Company Valuation Analysis: Categorization by Awards Score
  • Figure 9.6: Company Valuation Analysis: Categorization by Tweets Score
  • Figure 9.7: Company Valuation Analysis: Categorization by Twitter Followers Score
  • Figure 9.8: Company Valuation Analysis: Categorization by Number of Products
  • Figure 9.9: Company Valuation Analysis: Categorization by Uniqueness Score
  • Figure 9.10: Company Valuation Analysis: Categorization by Weighted Average Score
  • Figure 9.11: Company Valuation Analysis: Unicorns in Liquid Biopsy
  • Figure 10.1: Biocartis: Annual Revenues, 2012-2016 (EUR Million)
  • Figure 10.2: Idylla™: Steps of Operation
  • Figure 10.3: Biocept: Annual Revenues, 2012-2016 (USD Million)
  • Figure 10.4: Biodesix Lung Reflex Test: Steps of Operation
  • Figure 10.5: GeneStrat®: Clinical Validation Data
  • Figure 10.6: Genomic Health: Annual Revenues, 2010-2016 (USD Million)
  • Figure 10.7: Guardant360™: Steps of Operation
  • Figure 10.8: NeoGenomics Laboratory: Annual Revenues, 2010-2016 (USD Million)
  • Figure 10.9: NeoLAB™ Prostate: Steps of Operation
  • Figure 10.10: PlasmaSELECT™ R64: Steps of Operations
  • Figure 10.11: QIAGEN: Annual Revenues, 2010-2016 (USD Billion)
  • Figure 10.12: QIAGEN Sales, 2016: Distribution by Business Segments
  • Figure 10.13: Transgenomic: Annual Revenues, 2010 - Q1-Q3 2016 (USD Million)
  • Figure 10.14: ICEme Kit: Steps of Operation
  • Figure 10.15: Trovagene: Annual Revenues, 2010-2016 (USD Million)
  • Figure 11.1: Survey Analysis: Distribution by Geography
  • Figure 11.2: Survey Analysis: Seniority Levels of Respondents
  • Figure 11.3: Survey Analysis: Distribution by Type of Product Portfolio
  • Figure 11.4: Survey Analysis: Distribution by Type of Products / Services Offered
  • Figure 11.5: Survey Analysis: Distribution by Type of Application
  • Figure 11.6: Survey Analysis: Distribution by Availability of the Products
  • Figure 11.7: Survey Analysis: Likely Liquid Biopsy Market Size (2030)
  • Figure 11.8: Survey Analysis: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
  • Figure 12.1: Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
  • Figure 12.2: Liquid Biopsy Market (2017-2030): Base Scenario (USD Billion)
  • Figure 12.3: Liquid Biopsy Market: Share by Application (USD Billion, %)
  • Figure 12.4: Liquid Biopsy Market: Share by Indication (%)
  • Figure 12.5: Liquid Biopsy Market: Share by Type of Marker (%)
  • Figure 12.6: Liquid Biopsy Market: Share by Type of Sample (%)
  • Figure 12.7: Liquid Biopsy Market: Share by Geography (%)
  • Figure 12.8: Other Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
  • Figure 13.1: Non-Invasive Cancer Diagnostics Market (USD Billion), 2017, 2023 and 2030

List of Tables:

  • Table 3.1: Survival on Early Diagnosis of Cancer
  • Table 3.2: Cost of Biopsy for Different Cancer Indications (in USD)
  • Table 3.3: Common Endoscopic Procedures
  • Table 4.1: Examples of Tumor Markers
  • Table 5.1: Liquid Biopsy Tests: Development Landscape
  • Table 5.2: Liquid Biopsy Tests: Distribution by Type of Application
  • Table 5.3: Liquid Biopsy Tests: Distribution by Geographical Coverage
  • Table 5.4: Liquid Biopsy: Technologies
  • Table 5.5: Liquid Biopsy: Systems and Instruments
  • Table 7.1: Liquid Biopsy: Tests Profiled
  • Table 7.2: Liquid Biopsy: Systems / Technologies Profiled
  • Table 7.3: Comparison of Clinical Sensitivity of BioFluidica Technology and CELLSEARCH® Technology
  • Table 7.4: Cancertrack: Biomarkers Detected
  • Table 7.5: SMSEQ™ Platform: Genes Detected
  • Table 7.6: CellMax Life: Publications
  • Table 7.7: CellMax Life: Posters / Presentations at Different Conferences
  • Table 7.8: CELLSEARCH® CTC Test: Cut-offs for Disease Prognosis
  • Table 7.9: CELLSEARCH® CTC Test: Publications
  • Table 7.10: cobas® EGFR Mutation Test v2: Publications
  • Table 7.11: LiquidBiopsy® Rare Cell Isolation: Specifications
  • Table 7.12: Cynvenio Biosystems: Publications
  • Table 7.13: Cynvenio Biosystems: Posters / Presentations at Different Conferences
  • Table 7.14: Metastat: Site Specific Biomarkers
  • Table 7.15: R.G.C.C. Group: Publications
  • Table 7.16: R.G.C.C. Group: Posters at Different Conferences
  • Table 7.17: R.G.C.C. Group: Presentations at Different Conferences
  • Table 7.18: BEAMing Technology: Publications
  • Table 7.19: BEAMing Technology: Posters / Presentations at Different Conferences
  • Table 7.20: PrediSeq: Gene Panel
  • Table 7.21: ViewRNA™ CTC Kits: Key Features
  • Table 7.22: Velox™: Potential Indications
  • Table 7.23: ApoStream® System: Specifications
  • Table 7.24: Comparison Between ApoStream® CTC Platform and CELLSEARCH® CTC Platform
  • Table 7.25: ApoCell: Posters / Presentations at Different Conferences
  • Table 7.26: Parsortix™ System: Publications
  • Table 7.27: Parsortix™ System: Posters / Presentations at Different Conferences
  • Table 8.1: Liquid Biopsy Market: Funding Instances, 2011-2017
  • Table 8.2: Liquid Biopsy Market: Types of Funding Instances, 2011-2017
  • Table 9.1: Company Valuation Analysis: Sample Dataset
  • Table 9.2: Company Valuation Analysis: Weighted Average Evaluation
  • Table 9.3: Company Valuation Analysis: Estimated Valuation
  • Table 10.1: Liquid Biopsy: List of Companies Profiled
  • Table 10.2: Biocartis: Portfolio of Liquid Biopsy Tests
  • Table 10.3: Idylla™ ctBRAF Mutation Assay: Features
  • Table 10.4: Idylla™ ctKRAS Mutation Assay: Features
  • Table 10.5: Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay: Features
  • Table 10.6: Biocept: Portfolio of Liquid Biopsy Tests
  • Table 10.7: Biodesix: Funding Instances
  • Table 10.8: Biodesix: Portfolio of Liquid Biopsy Tests
  • Table 10.9: VeriStrat® Test: Publications
  • Table 10.10: Exosome Diagnostics: Funding Instances
  • Table 10.11: Exosome Diagnostics: Portfolio of Liquid Biopsy Tests
  • Table 10.12: Oncotype SEQ™ Liquid Select Mutation Panel: Clinical Results
  • Table 10.13: Guardant Health: Funding Instances
  • Table 10.14: NeoGenomics Laboratories: Portfolio of Liquid Biopsy Tests
  • Table 10.15: NeoLAB™ HEME: Multiplex Profiles
  • Table 10.16: NeoGenomics Laboratories: Publications
  • Table 10.17: Personal Genome Diagnostics: Funding Instances
  • Table 10.18: Personal Genome Diagnostics: Portfolio of Liquid Biopsy Tests
  • Table 10.19: MetDETECT™: Specifications
  • Table 10.20: QIAGEN: Portfolio of Liquid Biopsy Tests
  • Table 10.21: Q1Aamp® Circulating Nucleic Acid Kit: Specifications
  • Table 10.22: ICEme Kits: Number of Possible COSMIC Mutations and Insertions / Deletions
  • Table 10.23: Transgenomic: Portfolio of Liquid Biopsy Tests
  • Table 10.24: MX-ICP CRC Analysis: Genes Analyzed and Recommended Treatment Options
  • Table 10.25: MX-ICP Melanoma Analysis: Genes Analyzed and Recommended Treatment Options
  • Table 10.26: MX-ICP NSCLC Analysis: Genes Analyzed and Recommended Treatment Options
  • Table 10.27: MX-ICP: Single-Gene Liquid Biopsy Tests
  • Table 10.28: Trovagene: Portfolio of Liquid Biopsy Tests
  • Table 10.29: Trovera™ Tests: Posters / Presentations at Different Conferences
  • Table 11.1: Other Non-Invasive Cancer Diagnostics: Market Landscape
  • Table 11.2: Survey Response: Overview of the Participating Companies
  • Table 11.3: Survey Response: Seniority Level of Respondents
  • Table 11.4: Survey Response: Type of Product Portfolio
  • Table 11.5: Survey Response: Type of Products / Services Offered
  • Table 11.6: Survey Response: Type of Application
  • Table 11.7: Survey Response: Availability of the Products
  • Table 11.8: Survey Response: Likely Liquid Biopsy Market Size (2030)
  • Table 11.9: Survey Response: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
  • Table 12.1: Liquid Biopsy for Early Diagnosis: Forecast Assumptions and Data Points
  • Table 12.2: Liquid Biopsy for Patient Monitoring: Forecast Assumptions and Data Points
  • Table 12.3: Liquid Biopsy for Recurrence Monitoring: Forecast Assumptions and Data Points
  • Table 12.4: Key Indications: Forecast Assumptions and Data Points
  • Table 15.1: Worldwide Incidence: Distribution by Type of Cancer
  • Table 15.2: Lung Cancer: Estimated New Cases in 2016 (In Thousands)
  • Table 15.3: Breast Cancer: Estimated New Cases in 2016 (In Thousands)
  • Table 15.4: Colorectal Cancer: Estimated New Cases in 2016 (In Thousands)
  • Table 15.5: Liquid Biopsy Tests: Distribution by Development Stage
  • Table 15.6: Liquid Biopsy Tests: Distribution by Sample Type
  • Table 15.7: Liquid Biopsy Tests: Distribution by Type of Markers Detected
  • Table 15.8: Liquid Biopsy Tests: Distribution by Indication
  • Table 15.9: Liquid Biopsy Tests: Distribution by Type of Application
  • Table 15.10: Liquid Biopsy Tests: Distribution by Leading Players
  • Table 15.11: Liquid Biopsy Market: Cumulative Funding Instances, 2011-2017
  • Table 15.12: Liquid Biopsy Market: Cumulative Funding Amount, 2011-2017 (USD Billion)
  • Table 15.13: Liquid Biopsy Tests: Distribution by Type of Funding Instances, 2011-2017
  • Table 15.14: Liquid Biopsy Tests: Distribution by Total Amount Invested, 2011-2017 (USD Billion)
  • Table 15.15: Leading Players: Distribution by Number of Funding Instances
  • Table 15.16: Company Valuation Analysis: Valuation Ratios, Input Dataset
  • Table 15.17: Biocartis: Annual Revenues, 2012-2016 (EUR Million)
  • Table 15.18: Biocept: Annual Revenues, 2012-2016 (USD Million)
  • Table 15.19: GeneStrat: Clinical Validation Data
  • Table 15.20: Genomic Health: Annual Revenues, 2010-2016 (USD Million)
  • Table 15.21: NeoGenomics Laboratory: Annual Revenues, 2010-2016 (USD Million)
  • Table 15.22: QIAGEN: Annual Revenues, 2010-2016 (USD Billion)
  • Table 15.23: QIAGEN Sales, 2016: Distribution by Business Segments
  • Table 15.24: Transgenomic: Annual Revenues, 2010 - Q1-Q3 2016 (USD Million)
  • Table 15.25: Trovagene: Annual Revenues, 2010-2016 (USD Million)
  • Table 15.26: Survey Analysis: Distribution by Geography
  • Table 15.27: Survey Analysis: Seniority Levels of Respondents
  • Table 15.28: Survey Analysis: Distribution by Type of Product Portfolio
  • Table 15.29: Survey Analysis: Distribution by Type of Products / Services Offered
  • Table 15.30: Survey Analysis: Distribution by Type of Application
  • Table 15.31: Survey Analysis: Distribution by Availability of Products
  • Table 15.32: Survey Analysis: Likely Liquid Biopsy Market Size (2030)
  • Table 15.33: Survey Analysis: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
  • Table 15.34: Liquid Biopsy Market: Distribution of Patient Population into Risk Groups
  • Table 15.35: Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
  • Table 15.36: Non-Invasive Cancer Diagnostics Market (2017-2030): Optimistic Scenario (USD Billion)
  • Table 15.37: Non-Invasive Cancer Diagnostics Market (2017-2030): Conservative Scenario (USD Billion)
  • Table 15.38: Liquid Biopsy Market (2017-2030): Base Scenario (USD Billion)
  • Table 15.39: Liquid Biopsy Market (2017-2030): Optimistic Scenario (USD Billion)
  • Table 15.40: Liquid Biopsy Market (2017-2030): Conservative Scenario (USD Billion)
  • Table 15.41: Liquid Biopsy Market: Share by Application, (USD Billion, %)
  • Table 15.42: Liquid Biopsy Market: Share by Indication, (%)
  • Table 15.43: Liquid Biopsy Market: Share by Type of Marker, (%)
  • Table 15.44: Liquid Biopsy Market: Share by Type of Sample, (%)
  • Table 15.45: Liquid Biopsy Market: Share by Type of Marker, (%)
  • Table 15.46: Other Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
  • Table 15.47: Other Non-Invasive Cancer Diagnostics Market (2017-2030): Optimistic Scenario (USD Billion)
  • Table 15.48: Other Non-Invasive Cancer Diagnostics Market (2017-2030): Conservative Scenario (USD Billion)
  • Table 15.49: Non-Invasive Cancer Diagnostics Market (USD Billion), 2017, 2023 and 2030

Listed Companies:

The following companies and organizations have been mentioned in the report.

  • 1. 10 MED
  • 2. 360 Genomics
  • 3. Abbott
  • 4. Acadia Woods Partners
  • 5. Accel Biotech
  • 6. Accelerate Brain Cancer Cure
  • 7. AccuraGen
  • 8. Acecgt Life Science
  • 9. Acer
  • 10. Ackermans & van Haaren
  • 11. Acousys Biodevices
  • 12. AcuamarkDx
  • 13. Adaptive Biotechnologies
  • 14. Addario Lung Cancer Medical Institute (ALCMI)
  • 15. Admera Health
  • 16. AdnaGen
  • 17. Aetna
  • 18. Affymetrix
  • 19. Agena Bioscience
  • 20. Akademiska Hospital
  • 21. Alexandria Venture Investments
  • 22. Allegro Diagnostics
  • 23. Allele Frequency Community
  • 24. Allen & Company
  • 25. Alliance Global
  • 26. Alloy Ventures
  • 27. Almac Group
  • 28. Amadix
  • 29. AME Cloud Ventures
  • 30. America's Choice Provider Network
  • 31. American Association for Cancer Research
  • 32. American Lung Association
  • 33. American Society of Clinical Oncology
  • 34. American Urological Association
  • 35. AmeriHealth
  • 36. Amgen
  • 37. Amplitech
  • 38. Andreessen Horowitz
  • 39. Andros Mannenkliniek
  • 40. ANGLE
  • 41. Ann Arbor SPARK
  • 42. Anpac Bio
  • 43. ApoCell
  • 44. Apollo Hospital
  • 45. Appistry
  • 46. ARCH Venture Partners
  • 47. Arcus Ventures
  • 48. Array BioPharma
  • 49. Artiman Ventures
  • 50. ARUP Laboratories
  • 51. Aspire Capital Fund
  • 52. Asset Management Ventures
  • 53. Assurant
  • 54. Astellas Pharma
  • 55. Astia Angels
  • 56. AstraZeneca
  • 57. ATGen
  • 58. Athena Advisors
  • 59. Atlantic Cancer Research Institute
  • 60. Attikon University Hospital
  • 61. Aurelia Private Equity
  • 62. Aurora Diagnostics
  • 63. Aurum Ventures MKI
  • 64. AVEO Oncology
  • 65. AVIVA Biosciences
  • 66. AXON Dx
  • 67. Ballast Point Ventures
  • 68. Barts Cancer Institute
  • 69. Bayer Healthcare
  • 70. Baylor College of Medicine
  • 71. BC Biomedical Laboratories
  • 72. BC Cancer Agency
  • 73. Becton Dickinson
  • 74. Benaruca
  • 75. Betta Pharmaceuticals
  • 76. BGI Tech Solutions
  • 77. Bio.be
  • 78. Biocartis
  • 79. Biocept
  • 80. Biodesix
  • 81. BioFluidica
  • 82. Biogen
  • 83. Biognosys
  • 84. Biohit HealthCare
  • 85. Biological Dynamics
  • 86. BioMark Diagnostics
  • 87. bioMerieux
  • 88. Bio-Rad
  • 89. BioSense Medical
  • 90. Biosensors International
  • 91. Biotron Healthcare
  • 92. Biotype Diagnostics
  • 93. BioVeda
  • 94. BioVendor
  • 95. Biovest
  • 96. Bioyong Technology Company
  • 97. Birla Sun Life Insurance
  • 98. Blair Gastroenterology Associates
  • 99. Blisce
  • 100. Blue Cross and Blue Shield of Illinois
  • 101. Blue Cross and Blue Shield of Louisiana
  • 102. Blue Cross Blue Shield of Michigan
  • 103. Blue Ridge Capital
  • 104. Boreal Genomics
  • 105. Brand Capital
  • 106. Brandenburg Capital (BFBII)
  • 107. Breast Care Centre - Jefferson Health
  • 108. Breathtec Biomedical
  • 109. Brigham and Women's Hospital
  • 110. Bristol-Myers Squibb
  • 111. Cadence Bank
  • 112. Cahaba Government Benefit Administrators
  • 113. Cambridge Innovation Capital
  • 114. Cambridge Oncometrix
  • 115. Cancer Genetics
  • 116. Canopus Bioscience
  • 117. Capio Biosciences
  • 118. Capital Health Plan
  • 119. Capital Royalty Partners
  • 120. CareFirst
  • 121. Caris Life Sciences
  • 122. Casdin Capital
  • 123. Catholic Health Initiatives Centre for Translational Research
  • 124. CD Ventures
  • 125. CDBI Partners
  • 126. CeGaT
  • 127. CellMax Life
  • 128. Celsee Diagnostics
  • 129. Centro di Ricerche Oncologiche di Mercogliano (CROM)
  • 130. Cerba HealthCare
  • 131. Charles River Associates
  • 132. Cigna
  • 133. Circulogene Theranostics
  • 134. City of Hope Medical Center
  • 135. CKM Capital Partners
  • 136. Claremont Creek Ventures
  • 137. Clarient
  • 138. Clearbridge BioMedics
  • 139. Clearbridge BSA
  • 140. Clinical and Experimental Pharmacology Group, The University of Manchester
  • 141. Clinical Genomics
  • 142. CloudHealth Genomics
  • 143. Clovis Oncology
  • 144. CollabRx
  • 145. College of American Pathologists
  • 146. Color
  • 147. Columbia University
  • 148. Concentra
  • 149. CORE Diagnostics
  • 150. COTA Partners
  • 151. Counsyl
  • 152. Creatv MicroTech
  • 153. Crede Capital Group
  • 154. Cynvenio Biosystems
  • 155. CytoLumina Technologies
  • 156. CytoTrack
  • 157. Dana-Farber Cancer Institute
  • 158. Data Collective
  • 159. Datar Genetics
  • 160. DDL Diagnostic Laboratory
  • 161. Debiopharm Group
  • 162. Decheng Capital
  • 163. Deerfield Capital Management
  • 164. Department of Biopathology, Institut de Cancérologie de Lorraine (ICL)
  • 165. Department of Oncology, Vejle Hospital
  • 166. Department of Urology, Radboud University Medical Center
  • 167. DermTech
  • 168. DiaDx
  • 169. DiagnoCure
  • 170. Diagnologix
  • 171. Diagnostica Longwood
  • 172. Diffusion Capital Partners
  • 173. Domain Associates
  • 174. Dr Lal PathLabs
  • 175. Dr. Rosell Oncology Institute
  • 176. Drug Response Dx
  • 177. DSP BlackRock
  • 178. DT Capital Partners
  • 179. Dynacare
  • 180. Eastern Cooperative Oncology Group
  • 181. Edison Innovation VC Growth Fund
  • 182. EKF Molecular Diagnostics
  • 183. Eli Lilly
  • 184. EmblemHealth
  • 185. Emerge Venture
  • 186. EONE-DIAGNOMICS Genome Center
  • 187. Epic Sciences
  • 188. Epigenomics
  • 189. Epistem Pharmacogenomics
  • 190. Eta Diagnostics
  • 191. EUREKA
  • 192. European Medical Network for Translational Research in Ovarian Cancer (EUTROC)
  • 193. European Research Organization on Genital Infection and Neoplasia (EUROGIN)
  • 194. European Society for Medical Oncology
  • 195. Exact Sciences
  • 196. Exalenz Bioscience
  • 197. Exosome Diagnostics
  • 198. Exosome Sciences
  • 199. Exosomics Siena
  • 200. Fairview Health Services
  • 201. Federal Holding and Investment Company
  • 202. FedMed
  • 203. Felicis Ventures
  • 204. Fidelity Investments
  • 205. First Coast Service Options
  • 206. Flatiron Health
  • 207. Flemish Agency for Innovation & Entrepreneurship
  • 208. Florida Blue
  • 209. Fluxion Biosciences
  • 210. Forbion Capital Partners
  • 211. Formation 8
  • 212. Fortified Provider Network
  • 213. Foundation Medicine
  • 214. Franklin Synergy Bank
  • 215. Franklin Templeton Investments
  • 216. Fraunhofer Institute for Cell Therapy and Immunology
  • 217. Galaxy Health Network
  • 218. GATC Biotech
  • 219. GBP Scientific
  • 220. GE Ventures
  • 221. Genetic Technologies
  • 222. Genomac Research Institute
  • 223. Genomic Health
  • 224. Genomictree
  • 225. Genoptix
  • 226. Genostics
  • 227. GenSignia
  • 228. Gentris
  • 229. Georgetown Lombardi Comprehensive Cancer Center
  • 230. GILUPI
  • 231. Goldman Sachs Asset Management
  • 232. Google Ventures
  • 233. GRAIL
  • 234. Green Pine Capital Partners
  • 235. Greenwoods Private Equity Funds
  • 236. Group Health Cooperative
  • 237. Guardant Health
  • 238. Hancock Bank
  • 239. HarlePhil Ventures, Harle Group
  • 240. Harmony Partners
  • 241. Health Alliance Plan
  • 242. Health Canada
  • 243. Health Care Services Corporation
  • 244. Health Net
  • 245. HealthCor Partners Management
  • 246. Hemosure
  • 247. Heritage Group
  • 248. HIFU CLINIC Prostate Cancer Treatment Center
  • 249. Highmark
  • 250. High-Tech Gründerfonds
  • 251. Hitachi Chemical Diagnostics
  • 252. Hitachi High-Technologies Corporation
  • 253. Hologic
  • 254. Hooper Holmes Health and Wellness
  • 255. Horizon Blue Cross Blue Shield of New Jersey
  • 256. HTG Molecular Diagnostics
  • 257. Humana
  • 258. Hygieia Sciences
  • 259. IBM Watson
  • 260. iCellate Medical
  • 261. ICICI Prudential
  • 262. Illumina
  • 263. Imperial Innovations
  • 264. Incyte
  • 265. Independence BlueCross
  • 266. IndivuTest
  • 267. Inivata
  • 268. Innogene Kalbiotech
  • 269. Innovation Endeavors
  • 270. Inserm Transfert
  • 271. Insight Genetics
  • 272. Instituto Diagnostico Varelli
  • 273. Integrated Personalize Medicine
  • 274. Interpace Diagnostics
  • 275. Inventures
  • 276. IPS Genomix
  • 277. IVDiagnostics
  • 278. Janssen Diagnostics
  • 279. Sidney Kimmel Cancer Center, Thomas Jefferson University
  • 280. Jennison Associates
  • 281. Johns Hopkins University School of Medicine
  • 282. Johnson & Johnson Development Corporation
  • 283. Johnson & Johnson Innovation
  • 284. JoyingBio
  • 285. JP Morgan Chase
  • 286. Junson Capital
  • 287. Kadmon Corporation
  • 288. Kaiser Permanente
  • 289. Karolinska Institute
  • 290. KBC Bank
  • 291. Kearny Venture Partners
  • 292. KfW Bankengruppe
  • 293. Khosla Ventures
  • 294. Kleiner Perkins Caufield & Byers
  • 295. KMD Biomarker Diagnostics
  • 296. Kodiak Venture Partners
  • 297. Koninklijke Philips
  • 298. Korys
  • 299. Kotak Mahindra Bank
  • 300. Lab21
  • 301. Labco Quality Diagnostics
  • 302. LabCorp
  • 303. LabsMD
  • 304. Lakeshore ArchAngels
  • 305. Lantern Pharma
  • 306. LCM Genect
  • 307. LifeLabs
  • 308. Lightspeed Venture Partners
  • 309. Lilly Asia Ventures
  • 310. Liquid Biotech USA
  • 311. Livzon Pharmaceutical Group
  • 312. London Health Sciences Centre
  • 313. Louisiana State University
  • 314. Manipal Group
  • 315. Martinské bioptické centrum
  • 316. Massachusetts General Hospital
  • 317. Massey Cancer Centre
  • 318. Mayo Clinic
  • 319. Mayo Medical Laboratory
  • 320. MD Anderson Cancer Center
  • 321. MDNA Life Sciences
  • 322. MDxHealth
  • 323. MedGenome
  • 324. Medical Mutual of Ohio
  • 325. Medical University of Vienna
  • 326. MediLabs
  • 327. MedImmune
  • 328. MedSIR
  • 329. MedStar Georgetown University Hospital
  • 330. MedX Health
  • 331. MELA Sciences
  • 332. Memorial Sloan Kettering Cancer Center
  • 333. Menarini Silicon Biosystems
  • 334. Menssana Research
  • 335. Merck
  • 336. Merrill Lynch
  • 337. Metabiomics
  • 338. Metabolomic Technologies
  • 339. Metabolomx
  • 340. MetaCell
  • 341. Michael J. Fox Foundation
  • 342. Mikro Biyosistemler
  • 343. Milenia Labs
  • 344. MiNDERA
  • 345. Ministry of Health, Labour and Welfare, Japan
  • 346. Mirati Therapeutics
  • 347. Miroculus
  • 348. MiRXES
  • 349. MLabs, University of Michigan
  • 350. Mohr Davidow Ventures
  • 351. Molecular Pathology Laboratory Network
  • 352. MolecularMD
  • 353. Monashee Capital
  • 354. mtm laboratories
  • 355. MultiPlan
  • 356. Multiplicom
  • 357. Münchner Leukämie Labor (MLL)
  • 358. Myriad Genetics
  • 359. Nan Fung Group
  • 360. Nanjing Kaiyuan Growth Capital Investments
  • 361. NASA
  • 362. Natera
  • 363. National Cancer Institute, US
  • 364. National Cancer Research Institute, UK
  • 365. National Comprehensive Cancer Network, US
  • 366. National Government Services, US
  • 367. National Institutes of Health, US
  • 368. Nektar Therapeutics
  • 369. NEO New Oncology
  • 370. NeoGenomics Laboratories
  • 371. Neuberger Berman Group
  • 372. New Enterprise Associates
  • 373. New Jersey Economic Development Authority
  • 374. New Rhein Healthcare
  • 375. NGen Partners
  • 376. NGN Capital
  • 377. NM Genomix
  • 378. Nodexus
  • 379. Norgen Biotek
  • 380. Noridian,
  • 381. Palmetto GBA
  • 382. Northgate Capital
  • 383. Northwestern University
  • 384. Novartis
  • 385. NovioGendix
  • 386. Novitas Solutions
  • 387. NuGen
  • 388. Olivia Newton-John Cancer Centre
  • 389. Oncimmune
  • 390. OncoCyte Corporation
  • 391. OncoDNA
  • 392. Oncolys Biopharma
  • 393. OneVentures
  • 394. OrbiMed Advisors
  • 395. Ortho Biotech Oncology Research & Development
  • 396. Owlstone Medical
  • 397. Oxford Finance Corporation
  • 398. Pacific Edge
  • 399. Palapa Ventures
  • 400. Palex Medical
  • 401. Pangaea Biotech
  • 402. Papillon Capital
  • 403. Participatiemaatschappij Vlaanderen
  • 404. PathQC
  • 405. Pathway Genomics
  • 406. Pejman Mar Ventures
  • 407. Perelman School of Medicine, University of Pennsylvania
  • 408. PeriRx
  • 409. Personal Genome Diagnostics
  • 410. Pfizer
  • 411. Pfizer Venture Investments
  • 412. Phenomenome Discoveries
  • 413. Philips
  • 414. Philips Research
  • 415. Picomole Instruments
  • 416. Pilot Growth Equity
  • 417. Pink Lotus Breast Cancer
  • 418. PMV Tina Fund
  • 419. PNC Bank
  • 420. Polaris Partners
  • 421. Polymedco
  • 422. PrairieGold Venture Partners
  • 423. Predicine
  • 424. PreferredOne
  • 425. Premier
  • 426. Prime Genomics
  • 427. Prime Value Capital Management
  • 428. Principia Biopharma
  • 429. Priority Health Michigan
  • 430. Progenetics
  • 431. Promega Corporation
  • 432. Prostate Cancer Foundation
  • 433. ProXeom
  • 434. Pulmostics
  • 435. QIAGEN
  • 436. Quaker BioVentures
  • 437. Queen Mary University
  • 438. Quest Diagnostics
  • 439. RA Capital Management
  • 440. RainDance Technologies
  • 441. Rarecells Diagnostics
  • 442. RareCyte
  • 443. Redmile Group
  • 444. Regenerus Laboratories
  • 445. Regions Capital Markets
  • 446. Reliance Capital
  • 447. Research Genetic Cancer Centre (R.G.C.C.) Group
  • 448. Resolution Bioscience
  • 449. Response Genetics
  • 450. RMI Partners
  • 451. Robert H. Lurie Comprehensive Cancer Center, Northwestern University
  • 452. Roche
  • 453. Roche Venture Fund
  • 454. Rosemont Seneca Technology Partners
  • 455. Rosetta Genomics
  • 456. Roswell Park Cancer Institute
  • 457. Royal Philips Electronics
  • 458. SAGA Diagnostics
  • 459. SAIC-Frederick
  • 460. SMBRINVEST
  • 461. Samsung Medical Center
  • 462. San Antonio Military Medical Center
  • 463. Sanomics
  • 464. Sarah Cannon Research Institute (SCRI)
  • 465. ScheBo Biotech
  • 466. ScreenCell
  • 467. Seaside National Bank and Trust
  • 468. Sectoral Asset Management
  • 469. Selah Genomics
  • 470. Sequenom
  • 471. Sequoia Capital
  • 472. Shanghai Zhangjiang Science & Technology Investment Corporation (ZJSTIC)
  • 473. Siemens Healthcare Diagnostics
  • 474. Silicon Valley Bank
  • 475. SIMSYS
  • 476. Singlera Genomics
  • 477. Singulex
  • 478. Sividon Diagnostics
  • 479. SkyDeck
  • 480. Skyline Diagnostics
  • 481. Société Régionale d'Investissement de Wallonie
  • 482. Sofinim
  • 483. Sofinnova Ventures
  • 484. Sorgente Genetica
  • 485. SouthGenetics
  • 486. Southwest Oncology Group
  • 487. Spanish Ministry of Economy and Competitiveness (MINECO)
  • 488. Spectrum 28
  • 489. SPRING Seed Capital
  • 490. SRI International
  • 491. St. Louis Arch Angels
  • 492. StableBody Technologies
  • 493. Stanford-StartX Fund
  • 494. State Bank of India
  • 495. Strand Life Sciences
  • 496. STRATA Skin Sciences
  • 497. Stratose
  • 498. Streck
  • 499. Sungent Bioventure
  • 500. Sutter Hill Ventures
  • 501. SYGNIS
  • 502. Synlab Group
  • 503. Syno Capital
  • 504. Sysmex Corporation
  • 505. Sysmex Inostics
  • 506. T Rowe Price
  • 507. Takeda Pharmaceuticals
  • 508. Technion-Israel Institute of Technology
  • 509. Telegraph Hill Partners (THP)
  • 510. TEM Research
  • 511. Temasek Holdings
  • 512. Teneovita Medical Innovations
  • 513. Teva Pharmaceuticals
  • 514. The eNose Company
  • 515. The European Health Centre Innovation (EHC Innovation)
  • 516. The Huntington National Bank
  • 517. The Institute of Cancer Research
  • 518. The Pancreatic Cancer Action Network
  • 519. The University of Manchester
  • 520. The University of Michigan Comprehensive Cancer Center
  • 521. The Wistar Institute
  • 522. Therawis Diagnostics
  • 523. Thermo Fisher Scientific
  • 524. Third Kind Venture Capital
  • 525. Third Rock Ventures
  • 526. Third Security
  • 527. Thomas Jefferson University
  • 528. Three Rivers Provider Network
  • 529. thromboDx
  • 530. Tiger Management
  • 531. Tokai Pharmaceuticals
  • 532. Transgenomic
  • 533. Trovagene
  • 534. Tumor Bank Ovarian Cancer Network
  • 535. Ucare
  • 536. United HealthCare
  • 537. UnitedHealth Group
  • 538. Universitätsklinikum Knappschaftskrankenhaus Bochum
  • 539. University Hospital Brussels
  • 540. University Medical Centre Hamburg-Eppendorf
  • 541. University of Athens
  • 542. University of British Columbia
  • 543. University of California, Los Angeles
  • 544. University of California, San Diego
  • 545. University of California, San Francisco
  • 546. University of Colorado, Anschutz Medical Campus
  • 547. University of Duisburg-Essen
  • 548. University of Dusseldorf
  • 549. University of Melbourne
  • 550. University of Michigan
  • 551. University of Pennsylvania
  • 552. University of Rochester Medical Center
  • 553. University of Southern California (USC) Norris Comprehensive Cancer Centre
  • 554. University of Southern Denmark
  • 555. University of Texas
  • 556. Uppsala BIO
  • 557. US Oncology Research (USOR)
  • 558. US Preventive Services Task Force
  • 559. Valiance
  • 560. Vall d'Hebron Institute of Oncology
  • 561. Vancouver Prostate Centre
  • 562. Velox Biosystems
  • 563. Ventana Medical Systems
  • 564. Veridex
  • 565. Vertex Venture Holdings
  • 566. Viatar CTC Solutions
  • 567. Vinsovier
  • 568. Virginia Commonwealth University
  • 569. Vitatex
  • 570. VolitionRx
  • 571. Vortex Bioscience
  • 572. VU University Medical Center
  • 573. VWR International
  • 574. VyCAP
  • 575. WaveSense
  • 576. Wellcome Trust Sanger Institute
  • 577. Wellmark Blue Cross Blue Shield
  • 578. Wells Fargo Securities
  • 579. Wilmot Cancer Intitute, Uiverity of Rochester Medical Center
  • 580. Windham Venture Partners
  • 581. Wisconsin Physician Services
  • 582. Woodford Patient Capital Trust
  • 583. Wren Laboratories
  • 584. Yale University
  • 585. Yissum Research Development Company
Back to Top